References
1. Armitage JO, Weisenburger DD. New approach to classifying
non-Hodgkin’s lymphomas: clinical features of the major histologic
subtypes. Non-Hodgkin’s Lymphoma Classification Project. Journal of
Clinical Oncology. 1998;16(8):2780-95.
2. Gratzinger D, Zhao S, Tibshirani RJ, Hsi ED, Hans CP, Pohlman B, et
al. Prognostic significance of VEGF, VEGF receptors, and microvessel
density in diffuse large B cell lymphoma treated with
anthracycline-based chemotherapy. Laboratory investigation.
2008;88(1):38-47.
3. Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci
PF, et al. Angiogenic growth factors and endostatin in non‐Hodgkin’s
lymphoma. British journal of haematology. 1999;106(2):504-9.
4. Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, et al. Imatinib
disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood,
The Journal of the American Society of Hematology.
2013;121(26):5192-202.
5. Scarpino S, Di Napoli A, Taraboletti G, Cancrini A, Ruco LP.
Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP‐1)
expression in thyroid papillary carcinoma cells. The Journal of
Pathology: A Journal of the Pathological Society of Great Britain and
Ireland. 2005;205(1):50-6.
6. Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J. Expression of the
type-1 repeats of thrombospondin-1 inhibits tumor growth through
activation of transforming growth factor-β. The American journal of
pathology. 2004;165(2):541-52.
7. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ,
et al. Revised response criteria for malignant lymphoma. Journal of
clinical oncology. 2007;25(5):579-86.
8. Folkman J. Angiogenesis: an organizing principle for drug discovery?
Nature reviews Drug discovery. 2007;6(4):273-86.
9. Paydas S, Ergin M, Seydaoglu G, Erdogan S, Yavuz S. Pronostic
significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory
and viral factors in 88 cases with diffuse large B cell lymphoma and
review of the literature. Leukemia research. 2009;33(12):1627-35.
10. Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M, et al. In
vitro and in vivo production of vascular endothelial growth factor by
chronic lymphocytic leukemia cells. Blood, The Journal of the American
Society of Hematology. 2000;96(9):3181-7.
11. Doussis‐Anagnostopoulou IA, Talks KL, Turley H, Debnam P, Tan DC,
Mariatos G, et al. Vascular endothelial growth factor (VEGF) is
expressed by neoplastic Hodgkin–Reed–Sternberg cells in Hodgkin’s
disease. The Journal of Pathology: A Journal of the Pathological Society
of Great Britain and Ireland. 2002;197(5):677-83.
12. Foss Hd, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H.
Expression of vascular endothelial growth factor in lymphomas and
Castleman’s disease. The Journal of Pathology: A Journal of the
Pathological Society of Great Britain and Ireland. 1997;183(1):44-50.
13. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al.
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth
and migration. The Journal of clinical investigation.
2000;106(4):511-21.
14. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas J, Dias S. VEGFR-1
(FLT-1) activation modulates acute lymphoblastic leukemia localization
and survival within the bone marrow, determining the onset of
extramedullary disease. Blood. 2006;107(4):1608-16.
15. Riihijärvi S, Nurmi H, Holte H, Björkholm M, Fluge Ø, Pedersen LM,
et al. High serum vascular endothelial growth factor level is an adverse
prognostic factor for high‐risk diffuse large B‐cell lymphoma patients
treated with dose‐dense chemoimmunotherapy. European journal of
haematology. 2012;89(5):395-402.
16. Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation
in the serum concentrations of the angiogenic growth factors VEGF and
bFGF is an independent predictor of poor prognosis in non-Hodgkin
lymphoma: a single-institution study of 200 patients. Blood, The Journal
of the American Society of Hematology. 2000;96(12):3712-8.
17. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic
significance of microvessel density and vascular endothelial growth
factor (VEGF) expression in non-Hodgkin’s lymphoma. Leukemia &
lymphoma. 2003;44(12):2089-93.
18. Tzankov A, Heiss S, Ebner S, Sterlacci W, Schaefer G, Augustin F, et
al. Angiogenesis in nodal B cell lymphomas: a high throughput study.
Journal of Clinical Pathology. 2007;60(5):476-82.
19. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ.
Targeting the expression of platelet-derived growth factor receptor by
reactive stroma inhibits growth and metastasis of human colon carcinoma.
The American journal of pathology. 2006;169(6):2054-65.
20. Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, et al.
Development of a fully human anti-PDGFRβ antibody that suppresses growth
of human tumor xenografts and enhances antitumor activity of an
anti-VEGFR2 antibody. Neoplasia. 2009;11(6):594-604.
21. Sano H, Ueda Y, Takakura N, Takemura G, Doi T, Kataoka H, et al.
Blockade of platelet-derived growth factor receptor-β pathway induces
apoptosis of vascular endothelial cells and disrupts glomerular
capillary formation in neonatal mice. The American journal of pathology.
2002;161(1):135-43.
22. Albo D, Tuszynski G. Thrombospondin-1 up-regulates tumor cell
invasion through the urokinase plasminogen activator receptor in head
and neck cancer cells. Journal of Surgical Research. 2004;120(1):21-6.
23. Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U.
Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin’s
lymphomas. Leukemia research. 2008;32(2):243-50.